Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Kidney Cancer | Research article

53 years old is a reasonable cut-off value to define young and old patients in clear cell renal cell carcinoma: a study based on TCGA and SEER database

Authors: Fucai Tang, Zechao Lu, Chengwu He, Hanbin Zhang, Weijia Wu, Zhaohui He

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

The objectives of this study were to screen out cut-off age value and age-related differentially expressed genes (DEGs) in clear cell renal cell carcinoma (CCRCC) from Surveillance Epidemiology and End Results (SEER) database and The Cancer Genome Atlas (TCGA) database.

Methods

We selected 45,974 CCRCC patients from SEER and 530 RNA-seq data from TCGA database. The age cut-off value was defined using the X-tile program. Propensity score matching (PSM) was used to balance the differences between young and old groups. Hazard ratio (HR) was applied to evaluate prognostic risk of age in different subgroups. Age-related DEGs were identified via RNA-seq data. Survival analysis was used to assess the relationship between DEGs and prognosis.

Results

In this study, we divided the patients into young (n = 14,276) and old (n = 31,698) subgroups according to cut-off value (age = 53). Age > 53 years was indicated as independent risk factor for overall survival (OS) and cancer specific survival (CSS) of CCRCC before and after PSM. The prognosis of old group was worse than that in young group. Eleven gene were differential expression between the younger and older groups in CCRCC. The expression levels of PLA2G2A and SIX2 were related to prognosis of the elderly.

Conclusion

Fifty-three years old was cut-off value in CCRCC. The prognosis of the elderly was worse than young people. It remind clinicians that more attention and better treatment should be given to CCRCC patients who are over 53 years old. PLA2G2A and SIX2 were age-related differential genes which might play an important role in the poor prognosis of elderly CCRCC patients.

Ridge CA, Pua BB, Madoff DC. Epidemiology and staging of renal cell carcinoma. Semin Intervent Radiol. 2014;31(01):3–8. https://doi.org/10.1055/s-0033-1363837.CrossRefPubMedPubMedCentral

Liu K, Wang P, Zhu X, Bei Y, Zheng Z, Yan S. Disparities of age-based cancer-specific survival improvement with various clinicopathologic characteristics for kidney cancer. Cancer Manag Res. 2018;10:2259–68. https://doi.org/10.2147/CMAR.S169192.CrossRefPubMedPubMedCentral

Takada S, Namiki M, Takahara S, Matsumiya K, Kondoh N, Kokado Y, et al. Serum HGF levels in acute renal rejection after living related renal transplantation. Transpl Int. 1996;9(2):151–4. https://doi.org/10.1111/j.1432-2277.1996.tb00870.x.CrossRefPubMed

Meehan B, Appu S, St Croix B, Rak-Poznanska K, Klotz L, Rak J. Age-related properties of the tumour vasculature in renal cell carcinoma. BJU Int. 2011;107(3):416–24. https://doi.org/10.1111/j.1464-410X.2010.09569.x.CrossRefPubMed

Al-Janabi O, Wach S, Nolte E, et al. Piwi-like 1 and 4 gene transcript levels are associated with clinicopathological parameters in renal cell carcinomas. Biochim Biophys Acta. 1842;2014:686–90.

Yusim I, Mermershtain W, Neulander E, Eidelberg I, Gusakova I, Kaneti J. Influence of age on the prognosis of patients with renal cell carcinoma (RCC). Onkologie. 2002;25(6):548–50. https://doi.org/10.1159/000068626.CrossRefPubMed

Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9. https://doi.org/10.1158/1078-0432.CCR-04-0713.CrossRefPubMed

Taccoen X, Valeri A, Descotes JL, Morin V, Stindel E, Doucet L, et al. Renal cell carcinoma in adults 40 years old or less: young age is an independent prognostic factor for cancer-specific survival. Eur Urol. 2007;51(4):980–7. https://doi.org/10.1016/j.eururo.2006.10.025.CrossRefPubMed

Aziz A, May M, Zigeuner R, Pichler M, Chromecki T, Cindolo L, et al. Do young patients with renal cell carcinoma feature a distinct outcome after surgery? A comparative analysis of patient age based on the multinational CORONA database. J Urol. 2014;191(2):310–5. https://doi.org/10.1016/j.juro.2013.08.021.CrossRefPubMed

10.

Kang HW, Seo SP, Kim WT, Yun SJ, Lee SC, Kim WJ, et al. Impact of young age at diagnosis on survival in patients with surgically treated renal cell carcinoma: a multicenter study. J Korean Med Sci. 2016;31(12):1976–82. https://doi.org/10.3346/jkms.2016.31.12.1976.CrossRefPubMedPubMedCentral

11.

Kim JH, Park YH, Kim YJ, Kang SH, Byun SS, Hong SH. Is there a difference in clinicopathological outcomes of renal tumor between young and old patients? A multicenter matched-pair analysis. Scand J Urol. 2016;50(5):387–91. https://doi.org/10.1080/21681805.2016.1204621.CrossRefPubMed

12.

Komai Y, Fujii Y, Iimura Y, Tatokoro M, Saito K, Otsuka Y, et al. Young age as favorable prognostic factor for cancer-specific survival in localized renal cell carcinoma. Urology. 2011;77(4):842–7. https://doi.org/10.1016/j.urology.2010.09.062.CrossRefPubMed

13.

Jung EJ, Lee HJ, Kwak C, Ku JH, Moon KC. Young age is independent prognostic factor for cancer-specific survival of low-stage clear cell renal cell carcinoma. Urology. 2009;73(1):137–41. https://doi.org/10.1016/j.urology.2008.08.460.CrossRefPubMed

14.

Malouf GG, Camparo P, Oudard S, Schleiermacher G, Theodore C, Rustine A, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the juvenile RCC network. Ann Oncol. 2010;21(9):1834–8. https://doi.org/10.1093/annonc/mdq029.CrossRefPubMed

15.

Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O'Brien T, et al. Timing the landmark events in the evolution of clear cell renal cell Cancer: TRACERx renal. Cell. 2018;173(3):611–23. https://doi.org/10.1016/j.cell.2018.02.020.CrossRefPubMedPubMedCentral

16.

Malouf GG, Camparo P, Molinié V, Dedet G, Oudard S, Schleiermacher G, et al. Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. J Urol. 2011;185(1):24–9. https://doi.org/10.1016/j.juro.2010.08.092.CrossRefPubMed

17.

Birts CN, Barton CH, Wilton DC. Catalytic and non-catalytic functions of human IIA phospholipase A2. Trends Biochem Sci. 2010;35(1):28–35. https://doi.org/10.1016/j.tibs.2009.08.003.CrossRefPubMed

18.

Wu Y, Song T, Liu M, He Q, Chen L, Liu Y, et al. PPARG negatively modulates Six2 in tumor formation of clear cell renal cell carcinoma. DNA Cell Biol. 2019;38(7):700–7. https://doi.org/10.1089/dna.2018.4549.CrossRefPubMed

19.

Patel NH, Attwood KM, Hanzly M, et al. Comparative analysis of smoking as a risk factor among renal cell carcinoma histological subtypes. J Urol. 2012;194:640–6.CrossRef

20.

Kroeger N, Klatte T, Birkhäuser FD, Rampersaud EN, Seligson DB, Zomorodian N, et al. Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival. Cancer. 2012;118(7):1795–802. https://doi.org/10.1002/cncr.26453.CrossRefPubMed

21.

Golabek T, Bukowczan J, Szopinski T, et al. Obesity and renal cancer incidence and mortality--a systematic review of prospective cohort studies. Ann Agric Environ Med. 2016;23:37–43.CrossRef

22.

Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. Obesity and cancer--mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol. 2014;10(8):455–65. https://doi.org/10.1038/nrendo.2014.94.CrossRefPubMedPubMedCentral

23.

Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7:245–57.CrossRef

24.

Colt JS, Schwartz K, Graubard BI, et al. Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology. 2011;22:797–804.CrossRef

Title: 53 years old is a reasonable cut-off value to define young and old patients in clear cell renal cell carcinoma: a study based on TCGA and SEER database
Authors: Fucai Tang
Zechao Lu
Chengwu He
Hanbin Zhang
Weijia Wu
Zhaohui He
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Kidney Cancer
Kidney Cancer
Kidney Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08376-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Bridging the research to practice gap: a systematic scoping review of implementation of interventions for cancer-related fatigue management

Associations of specific-age and decade recall body mass index trajectories with obesity-related cancer

Secondhand smoke exposure, diabetes, and high BMI are risk factors for uterine cervical cancer: a cross-sectional study from the Korea national health and nutrition examination survey (2010–2018)

Extracellular vesicles shed from gastric cancer mediate protumor macrophage differentiation

Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer